Use of the Hansen Medical System in Patients With Paroxysmal Atrial Fibrillation


The purpose of this study is to assess the safety and performance of the Hansen Medical Sensei Robotic System and Artisan Catheter when used to robotically manipulate RF ablation catheters for the treatment of paroxysmal atrial fibrillation (irregular heartbeats originating in the upper chambers of the heart).

Full Title of Study: “A Prospective, Single Arm Study of the Hansen System for Introducing and Positioning RF Ablation Catheters in Subjects With Paroxysmal Atrial Fibrillation”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: April 2017

Detailed Description

Subjects who satisfy the inclusion and exclusion criteria will be treated with an RF ablation catheter and Artisan guide catheters controlled by the Sensei X Robotic Catheter System. Subject will be followed for a period of one year post ablation procedure. Follow up visit time frames will be conducted at 7-day, 30-day, 90-day, 180-day and 365-day.


  • Device: Ablation
    • Atrial fibrillation ablation procedure

Arms, Groups and Cohorts

  • Experimental: Robotic catheter manipulation, Ablation
    • To evaluate the safety and effectiveness of the family of Artisan guide catheters when used to remotely introduce and position commercially available cardiac RF ablation catheters to treat subjects with paroxysmal atrial fibrillation.

Clinical Trial Outcome Measures

Primary Measures

  • Safety-Incidence of Major Complications
    • Time Frame: within 7 days of the ablation procedure nd the incidence of esophageal injury or pulmonary vein stenosis through 180 days
    • The primary safety endpoint was defined as the incidence of major complications, including all early onset (within 7 days of the ablation procedure) major complications, and the incidence of esophageal injury or pulmonary vein stenosis through 180 days.
  • Effectiveness-Freedom From Symptomatic Atrial Fibrillation (AF), Atrial Flutter, and Atrial Tachycardia Episodes
    • Time Frame: 91 – 365 days after the inital ablation procedure
    • The primary effectiveness endpoint is chronic success as demonstrated by the freedom from symptomatic atrial arrhythmia from days 91 to 365.

Secondary Measures

  • Acute Procedural Success
    • Time Frame: Day 0
    • Acute procedural success is defined as the successful ablation of at least three of four pulmonary veins as shown by pulmonary vein entrance block per vein during the initial ablation procedure. A subject is considered to be an acute procedural failure if acute procedural success cannot be obtained by using the Hansen system and, as a result, manual manipulation is needed to complete the ablation procedure with the ablation catheter.
  • Chronic Safety-Incidence of Major Complications
    • Time Frame: 8 – 365 days post-procedure
    • Chronic safety is defined as the incidence of Major Complications during the period from 8 – 365 days following the initial ablation procedure (excluding pulmonary vein stenosis and atrio-esophageal fistula from 8 – 180 days, which are included in the primary safety endpoint). The incidence of pulmonary vein stenosis and atrioesophageal fistula is included during the period from 181 – 365 days.

Participating in This Clinical Trial

Inclusion Criteria

1. Subjects with paroxysmal atrial fibrillation who have had two or more spontaneously terminating episodes of atrial fibrillation, that last longer than 30 seconds and shorter than 7 days, in the nine months prior to enrollment. At least one episode must be documented with EKG, TTM, Holter monitor, or telemetry. 2. Failure of at least one Class I – IV anti-arrhythmic drug (AAD) for PAF as evidenced by recurrent symptomatic PAF, or intolerable side effects due to AADs. AADs are defined in Appendix B. 3. Signed informed consent. 4. Age 18 years or older 5. Able and willing to comply with all pre-, post-, and follow-up testing and requirements. Exclusion Criteria:

1. Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause. 2. Previous ablation for atrial fibrillation. 3. Atrial fibrillation episodes that last less than 7 days and are terminated by cardioversion. 4. Previous valvular cardiac surgery procedure. 5. Cardiac artery bypass graft procedure within the previous 180 days. 6. Previous septal defect repair. 7. Expecting cardiac transplantation or other cardiac surgery within the next 180 days. 8. Coronary PTCA/stenting within the previous 180 days. 9. Documented left atrial thrombus on ultrasound imaging (TEE). 10. Documented history of a thrombo-embolic event within the previous 365 days. 11. Diagnosed atrial myxoma. 12. Presence of an implanted ICD. 13. Presence of permanent pacing leads. 14. Significant restrictive, constrictive, or chronic obstructive pulmonary disease or any other disease or malfunction of the lungs or respiratory system with chronic symptoms. 15. Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study. 16. Women who are pregnant. 17. Acute illness or active infection at time of index procedure documented by either pain, fever, drainage, positive culture and/or leukocytosis (WBC > 11,000 mm3) for which antibiotics have been or will be prescribed. 18. Creatinine > 2.5 mg/dl (or > 221 µmol/L). 19. Unstable angina. 20. Myocardial infarction within the previous 60 days. 21. Left ventricular ejection fraction less than 40% 22. History of blood clotting or bleeding abnormalities. 23. Contraindication to anticoagulation medications. 24. Contraindication to computed tomography or magnetic resonance imaging procedures. 25. Life expectancy less than 1 year. 26. Enrollment in another investigational study. 27. Uncontrolled heart failure (NYHA class III or IV heart failure). 28. Presence of an intramural thrombus, tumor, or other abnormality that precludes catheter introduction or positioning. 29. Presence of a condition that precludes vascular access. 30. Left atrial size ≥ 50mm. 31. INR greater than 3.0 within 24 hours of procedure.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Hansen Medical
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Joseph Gallinghouse, M.D., Principal Investigator, Texas Cardiac Arrhythmia Research Foundation
    • Andrea Natale, M.D., Principal Investigator, Texas Cardiac Arrhythmia Research Foundation
    • Brenda Cayme, RN., BSN, Study Director, Hansen Medical, Inc.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.